Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutation Rate of AmpC β-Lactamase–Producing Enterobacterales and Treatment in Clinical Practice: A Word of Caution

25 Mar 2024

Abstract excerpt

In a retrospective multicenter study of 575 patients with bloodstream infections or pneumonia due to wild-type AmpC β-lactamase-producing Enterobacterales, species with low in vitro mutation rates for AmpC derepression were associated with fewer treatment failures due to AmpC overproduction (adjusted hazard ratio, 0.5 [95% CI, .2-.9]). However, compared to cefepime/carbapenems, using third-generation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotic Resistance in Bacteria
Share to Antibiotics Pharmacokinetics and Efficacy
Share to Pneumonia and Respiratory Infections

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38527853
DOI: 10.1093/cid/ciae160

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutation Rate of AmpC β-Lactamase–Producing Enterobacterales and Treatment in Clinical Practice: A Word of CautionPMID 38527853Read ↗

Species-specific mutation rates for ampC derepression in Enterobacterales with chromosomally encoded inducible AmpC β-lactamaseSemantic proximity Read ↗

Selection of mutants with resistance or diminished susceptibility to ceftazidime/avibactam from ESBL- and AmpC-producing EnterobacteriaceaeSemantic proximity Read ↗

Clinical Outcomes of Third-Generation Cephalosporins, Carbapenems, and Piperacillin-Tazobactam in the Treatment of AmpC- Associated Enterobacterales Species SepsisSemantic proximity Read ↗

Piperacillin-Tazobactam versus Other Antibacterial Agents for Treatment of Bloodstream Infections Due to AmpC β-Lactamase-Producing Enterobacteriaceae.Semantic proximity Read ↗

Correlation between the mutation rates for ampC derepression and species or ampC genotypes in Enterobacter cloacae complex.Semantic proximity Read ↗

Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic optionsSemantic proximity Read ↗

Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type β-lactamases.Semantic proximity Read ↗

Evaluation of six commercial and in-house phenotypic tests for detection of AmpC β-lactamases: is routine detection possible?Semantic proximity Read ↗

Piperacillin-tazobactam should be preferred to third-generation cephalosporins to treat wild-type inducible AmpC-producing Enterobacteriaceae in critically ill patients with hospital or ventilator-acquired pneumonia. A propensity score-matched analysisSemantic proximity Read ↗

Heteroresistance to cefiderocol in carbapenem-resistant Acinetobacter baumannii in the CREDIBLE-CR study was not linked to clinical outcomes: a post hoc analysisSemantic proximity Read ↗

Positive Extended-Spectrum-β-Lactamase (ESBL) Screening Results May Be Due to AmpC β-Lactamases More Often than to ESBLsSemantic proximity Read ↗

Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015–16Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.